Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

TAKBullishIndustry Newsnews

High materiality7/10

Takeda reports positive LATITUDE Phase 3 data for TAK-279 psoriasis program

Sep 30, 2026, 1:13 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Positive Phase 3 data can improve the probability of regulatory milestones and expand the psoriasis TAM for Takeda, though no approval yet creates a binary risk.

AI summary

What happened, with direct paths to the underlying reporting

Takeda announced new Phase 3 LATITUDE data for zasocitinib (TAK-279), its TYK2 inhibitor, across three psoriasis studies in adults with moderate-to-severe disease, presented at EADV 2026. While early, consistent Phase 3 readouts could de-risk the program and support potential regulatory milestones, potentially expanding Takeda's TYK2 franchise and psoriasis portfolio.

Takeda reports Phase 3 LATITUDE data for TAS-279 (zasocitinib) in psoriasis.
Three LATITUDE trials show efficacy in plaque psoriasis; data at EADV 2026.
TAK-279 is a selective oral TYK2 inhibitor in adults with moderate-to-severe disease.
Results may impact regulatory timelines and broaden Takeda's TYK2 psoriasis portfolio.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Takeda reports positive LATITUDE Phase 3 data for TAK-279 psoriasis program

Takeda-Protagonist FDA approval boosts rare-disease drug prospects and partnerships

FDA approves Takeda narcolepsy drug with all-symptom coverage

Takeda's QDENGA gains India approval, potential dengue vaccine growth catalyst

Takeda's zasocitinib yields ~70% clearance; NDA filing planned